Targetable cellular signaling events mediate vascular pathology in vascular Ehlers-Danlos syndrome

J Clin Invest. 2020 Feb 3;130(2):686-698. doi: 10.1172/JCI130730.

Abstract

Vascular Ehlers-Danlos syndrome (vEDS) is an autosomal-dominant connective tissue disorder caused by heterozygous mutations in the COL3A1 gene, which encodes the pro-α 1 chain of collagen III. Loss of structural integrity of the extracellular matrix is believed to drive the signs and symptoms of this condition, including spontaneous arterial dissection and/or rupture, the major cause of mortality. We created 2 mouse models of vEDS that carry heterozygous mutations in Col3a1 that encode glycine substitutions analogous to those found in patients, and we showed that signaling abnormalities in the PLC/IP3/PKC/ERK pathway (phospholipase C/inositol 1,4,5-triphosphate/protein kinase C/extracellular signal-regulated kinase) are major mediators of vascular pathology. Treatment with pharmacologic inhibitors of ERK1/2 or PKCβ prevented death due to spontaneous aortic rupture. Additionally, we found that pregnancy- and puberty-associated accentuation of vascular risk, also seen in vEDS patients, was rescued by attenuation of oxytocin and androgen signaling, respectively. Taken together, our results provide evidence that targetable signaling abnormalities contribute to the pathogenesis of vEDS, highlighting unanticipated therapeutic opportunities.

Keywords: Cardiology; Collagens; Genetic diseases; Mouse models; Vascular Biology.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aortic Rupture* / drug therapy
  • Aortic Rupture* / genetics
  • Aortic Rupture* / metabolism
  • Aortic Rupture* / pathology
  • Collagen Type III* / genetics
  • Collagen Type III* / metabolism
  • Disease Models, Animal
  • Ehlers-Danlos Syndrome* / drug therapy
  • Ehlers-Danlos Syndrome* / genetics
  • Ehlers-Danlos Syndrome* / metabolism
  • Ehlers-Danlos Syndrome* / pathology
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • MAP Kinase Signaling System* / drug effects
  • MAP Kinase Signaling System* / genetics
  • Mice
  • Mice, Transgenic
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 1 / genetics
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / genetics
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Mutation
  • Protein Kinase C beta / antagonists & inhibitors
  • Protein Kinase C beta / genetics
  • Protein Kinase C beta / metabolism

Substances

  • COL3A1 protein, mouse
  • Collagen Type III
  • Enzyme Inhibitors
  • Prkcb protein, mouse
  • Protein Kinase C beta
  • Mapk1 protein, mouse
  • Mapk3 protein, mouse
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3